LifeVantage Corporation — Form 10-Q Summary
Reporting period: Three months ended September 30, 2022, the first quarter of fiscal 2023—not calendar-year 2022 Q1. Financial statements are unaudited. LifeVantage sells nutrition, wellness, personal-care and related products through independent distributors and direct sales.
Financial performance and liquidity
| Metric | Q1 FY2023 | Q1 FY2022 |
|---|---|---|
| Revenue | $51.8 million | $53.2 million |
| Gross profit / margin | $41.8 million / 80.8% | $43.8 million / 82.3% |
| Operating income / margin | $1.3 million / 2.5% | $4.6 million / 8.7% |
| Net income / diluted EPS | $0.6 million / $0.05 | $3.3 million / $0.25 |
| Operating cash flow | $(1.3) million | $0.5 million |
| Capital expenditures | $0.7 million | $0.4 million |
- Cash and cash equivalents were $17.6 million at September 30, down $2.6 million from June 30. Working capital was $20.2 million; the current ratio was approximately 1.9.
- Total liabilities were $35.7 million, including $15.0 million of lease liabilities. The company had repaid its term loan in fiscal 2020; the filing does not state a balance drawn on the $5.0 million revolving facility.
- Cash used in operations included higher inventory and decreases in accrued expenses. The company paid $0.4 million in dividends and reported no share repurchases in the quarter.
Changes versus the prior comparable quarter
- Revenue fell 2.7%. Foreign exchange reduced reported revenue by approximately $2.7 million; Asia/Pacific & Europe revenue declined 8.2%, while Americas revenue was nearly flat.
- Japan revenue declined 17.0% as reported, but increased 3.2% on a constant-currency basis. Revenue in Australia and New Zealand fell 40.9%.
- Active accounts declined 6.7% to 153,000, including an 11.8% decrease in active customers. Active distributors increased 1.6% to 63,000.
- Gross margin declined 1.5 percentage points, attributed to shipping costs and geographic and product mix. SG&A increased 11.0% to $16.7 million, driven by event and travel costs, legal fees, endorsement agreements, product testing, and salaries and wages.
- Operating income fell 72.0%; net income fell 81.6%. Foreign-currency losses contributed to other expense, which was $0.4 million versus $0.2 million.
Outlook, risks and notable items
- Management expects product launches and continued product expansion in fiscal 2023 to support revenue growth by increasing average order size and attracting and retaining customers and distributors. No numerical revenue or earnings guidance is provided.
- Management believes cash and expected operating cash flows will meet requirements for at least the next 12 months, while noting that additional financing, if needed, may not be available on acceptable terms. The company was in compliance with its credit-facility covenants at quarter-end and anticipated continued compliance.
- A September 30, 2022 credit-facility amendment revised the fixed-charge-coverage-ratio calculation and permitted dividends of up to $500,000 per quarter through September 30, 2023. The facility matures March 31, 2024 and is secured by substantially all company assets.
- COVID-19-related disruptions, including closures and limits on in-person distributor activity in some international markets, continued to affect operations. Management also cited supply-chain, foreign-exchange, distributor-retention, product-acceptance, regulatory and direct-selling risks.
- In the Smith class action, the court denied class certification in April 2022 and stayed the case through November 25, 2022. The company recorded no litigation accrual, stating that loss was not probable or estimable; an unfavorable outcome could still be material.
- The company reported no material changes to previously disclosed risk factors and no material changes in internal control over financial reporting; disclosure controls were assessed as effective.
Investor facts to verify
- Whether distributor and customer account trends, particularly the decline in active customers, improve in subsequent quarters.
- How much of reported revenue weakness reflects foreign exchange versus underlying sales, and whether product launches offset regional declines.
- Whether lower gross margin, elevated SG&A, and operating cash outflows persist.
- The actual amount, availability and covenant headroom of the revolving credit facility; the filing does not provide a clear drawn-balance figure.
- Developments in the Smith litigation and any change in management’s assessment of potential loss.